@DamnRay 1 month ago
Ultragenyx had one of the worst moves in the market
Ultragenyx had one of the worst moves in the market
crashed around 44% after a key drug failed in a late stage clinical trial. This is exactly why biotech investing can be brutal, years of expectations can change in one trial result. Hoping you weren't invested in the company
@CopyRemarkable14 1 month ago
Biotech can be incredibly unforgiving, one trial result can completely change the story overnight.
@bennettOlivia7 1 month ago
Yeah, I agree. Oracle has plenty of AI demand behind it, but the next step is proving that all that infrastructure investment can translate into durable growth and better returns.
